Differential expression and effects of gp130 cytokines and receptors in prostate cancer cells

International Journal of Biochemistry and Cell Biology

Volumn 36, Issue 11, 2004, Pages 2258-2269

  Palmer, J ^a   Hertzog, P J ^a   Hammacher, A ^b  

^a MONASH UNIVERSITY   (Australia)

^b Bernard O'Brien Institute of Microsurgery   (Australia)

Author keywords

cardiotrophin 1; CgA; chromogranin A; ciliary neurotrophic factor; CNTF; CT1; DCV; dense core vesicle; EDTA; ethylenedinitrilo tetraacetic acid; FBS; foetal bovine serum; IL6; interleukin 6; leukemia inhibitory factor; LIF; NE; neuroendocrine; NSE

Indexed keywords

CYTOKINE; GLYCOPROTEIN GP 130; INTERLEUKIN 6; STAT3 PROTEIN;

ARTICLE; CANCER CELL CULTURE; CELL DIFFERENTIATION; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; NEUROSECRETORY CELL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; SOUTHERN BLOTTING; TRANSMISSION ELECTRON MICROSCOPY;

ANTIGENS, CD; CELL DIFFERENTIATION; CELL PROLIFERATION; CYTOKINE RECEPTOR GP130; CYTOKINES; DNA-BINDING PROTEINS; HUMANS; INTERLEUKIN-6; LEUKEMIA INHIBITORY FACTOR; MALE; MEMBRANE GLYCOPROTEINS; MICROSCOPY, ELECTRON, TRANSMISSION; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEINS; SIGNAL TRANSDUCTION; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR CELLS, CULTURED;

BOVINAE; DROSOPHILA C VIRUS;

EID: 4143060404     PISSN: 13572725     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biocel.2004.04.017     Document Type: Article

References (32)

1. Abrahamsson P.A. Neuroendocrine differentiation in prostatic carcinoma. Prostate. 39:1999;135-148
2. ABS (2002). Year book Australia 2002: Health cancer control. Australian Bureau of Statistics.
3. Borsellino N., Bonavida B., Ciliberto G., Toniatti C., Travali S., D'Alessandro N. Blocking signaling through the Gp130 receptor chain by interleukin-6 and oncostatin M inhibits PC-3 cell growth and sensitizes the tumor cells to etoposide and cisplatin-mediated cytotoxicity. Cancer. 85:1999;134-144
4. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Analytical Biochemistry. 162:1987;156-159
5. Chung T.D., Yu J.J., Spiotto M.T., Bartkowski M., Simons J.W. Characterization of the role of IL-6 in the progression of prostate cancer. Prostate. 38:1999;199-207
6. Corcoran N.M., Costello A.J. Interleukin-6: Minor player or starring role in the development of hormone-refractory prostate cancer? BJU International. 91:2003;543-553
7. Culig Z., Hobisch A., Cronauer M.V., Radmayr C., Hittmair A., Zhang J., et al. Regulation of prostatic growth and function by peptide growth factors. Prostate. 28:1996;392-405
8. Djakiew D. Dysregulated expression of growth factors and their receptors in the development of prostate cancer. Prostate. 42:2000;150-160
9. Douglas A.M., Goss G.A., Sutherland R.L., Hilton D.J., Berndt M.C., Nicola N.A., et al. Expression and function of the cytokine receptor superfamily on breast cancer cells. Oncogene. 14:1997;661-669
10. Drachenberg D.E., Elgamal A.A., Rowbotham R., Peterson M., Murphy G.P. Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate. 41:1999;127-133
11. Giri D., Ozen M., Ittmann M. Interleukin-6 is an autocrine growth factor in human prostate cancer. American Journal of Pathology. 159:2001;2159-2165
12. Hammacher A., Richardson R.T., Layton J.E., Smith D.K., Angus L.J., Hilton D.J., et al. The immunoglobulin-like module of gp130 is required for signaling by interleukin-6, but not by leukemia inhibitory factor. Journal of Biological Chemistry. 273:1998;22701-22707
13. Hammacher A., Ward L.D., Weinstock J., Treutlein H., Yasukawa K., Simpson R.J. Structure-function analysis of human IL-6: Identification of two distinct regions that are important for receptor binding. Protein Science. 3:1994;2280-2293
14. Heinrich P.C., Behrmann I., Muller-Newen G., Schaper F., Graeve L. Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. Biochemistry Journal. 334:1998;297-314
15. Hobisch A., Rogatsch H., Hittmair A., Fuchs D., Bartsch G. Jr., Klocker H., et al. Immunohistochemical localisation of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. Journal of Pathology. 191:2000;239-244
16. Lee S.O., Lou W., Hou M., de Miguel F., Gerber L., Gao A.C. Interleukin-6 promotes androgen-independent growth in LNCaP human prostate cancer cells. Clinical Cancer Research. 9:2003;370-376
17. Lou W., Ni Z., Dyer K., Tweardy D.J., Gao A.C. Interleukin-6 induces prostate cancer cell growth accompanied by activation of Stat3 signaling pathway. Prostate. 42:2000;239-242
18. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., et al. Constitutive activation of Stat3 in human prostate tumors and cell lines: Direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Research. 62:2002;6659-6666
19. Mori S., Murakami-Mori K., Bonavida B. Oncostatin M (OM) promotes the growth of DU 145 human prostate cancer cells, but not PC-3 or LNCaP, through the signaling of the OM specific receptor. Anticancer Research. 19:1999;1011-1015
20. Okamoto M., Lee C., Oyasu R. Interleukin-6 as a paracrine and autocrine growth factor in human prostatic carcinoma cells in vitro. Cancer Research. 57:1997;141-146
21. Parkin D.M., Pisani P., Ferlay J. Estimates of the worldwide incidence of 25 major cancers in 1990. International Journal of Cancer. 80:1999;827-841
22. Pfitzenmaier J., Vessella R., Higano C.S., Noteboom J.L., Wallace D. Jr., Corey E. Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer. 97:2003;1211-1216
23. Qiu Y., Ravi L., Kung H.J. Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature. 393:1998;83-85
24. Qiu Y., Robinson D., Pretlow T.G., Kung H.J. Etk/Bmx, a tyrosine kinase with a pleckstrin-homology domain, is an effector of phosphatidylinositol 3(-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proceedings of the National Academy of Sciences USA. 95:1998;3644-3649
25. Shariat S.F., Andrews B., Kattan M.W., Kim J., Wheeler T.M., Slawin K.M. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. Urology. 58:2001;1008-1015
26. Siegsmund M.J., Yamazaki H., Pastan I. Interleukin 6 receptor mRNA in prostate carcinomas and benign prostate hyperplasia. Journal of Urology. 151:1994;1396-1399
27. Simpson R.J., Hammacher A., Smith D.K., Matthews J.M., Ward L.D. Interleukin-6: Structure-function relationships. Protein Science. 6:1997;929-955
28. Society., A. C. (2003). Cancer facts and figures 2003. Georgia: American Cancer Society.
29. Spiotto M.T., Chung T.D. STAT3 mediates IL-6-induced neuroendocrine differentiation in prostate cancer cells. Prostate. 42:2000;186-195
30. Taga T., Kishimoto T. Gp130 and the interleukin-6 family of cytokines. Ann. Rev. Immunol. 15:1997;797-819
31. Tanigawa T., Nicola N., McArthur G.A., Strasser A., Begley C.G. Differential regulation of macrophage differentiation in response to leukemia inhibitory factor/oncostatin-M/interleukin-6: The effect of enforced expression of the SCL transcription factor. Blood. 85:1995;379-390
32. Twillie D.A., Eisenberger M.A., Carducci M.A., Hseih W.S., Kim W.Y., Simons J.W. Interleukin-6: A candidate mediator of human prostate cancer morbidity. Urology. 45:1995;542-549